Analysis of clinical prostate cancer genomic datasets indicates that RYK gene amplification occurs in 2–2.7% and 2.7–7.2% in primary and metastatic cases, respectively (Table 1 and Tables S1–S4) [64,65,66], indicating a higher frequency occurs in advanced disease. Here, RYK is linked to prostate carcinoma.